119 related articles for article (PubMed ID: 2934581)
61. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
Lemay A; Jean C; Faure N
Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
[TBL] [Abstract][Full Text] [Related]
62. Evidence for a specific role of GnRH pulse frequency in the control of the human menstrual cycle.
Filicori M; Flamigni C; Campaniello E; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A; Valdiserri A
Am J Physiol; 1989 Dec; 257(6 Pt 1):E930-6. PubMed ID: 2514600
[TBL] [Abstract][Full Text] [Related]
63. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial.
Penzias AS; Shamma FN; Gutmann JN; Jones EE; DeCherney AH; Lavy G
Obstet Gynecol; 1992 May; 79(5 ( Pt 1)):739-42. PubMed ID: 1533022
[TBL] [Abstract][Full Text] [Related]
64. Comparison of HMG/HCG superovulation for AID with or without superactive GnRH agonist.
Gerris J; Jacquemyn Y; Desmedt E; Delbeke L; Buytaert P
Hum Reprod; 1989 Nov; 4(8):937-40. PubMed ID: 2515211
[TBL] [Abstract][Full Text] [Related]
65. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
66. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin.
Pirard C; Donnez J; Loumaye E
Hum Reprod; 2005 Jul; 20(7):1798-804. PubMed ID: 15890740
[TBL] [Abstract][Full Text] [Related]
67. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
68. Long-term reversible suppression of oestrus in bitches with nafarelin acetate, a potent LHRH agonist.
McRae GI; Roberts BB; Worden AC; Bajka A; Vickery BH
J Reprod Fertil; 1985 Jul; 74(2):389-97. PubMed ID: 2931517
[TBL] [Abstract][Full Text] [Related]
69. Recent developments in female contraception: LHRH.
Vijayan E
J Steroid Biochem; 1985 Nov; 23(5B):827-31. PubMed ID: 3935868
[TBL] [Abstract][Full Text] [Related]
70. Chronic treatment with a LH-RH-agonist: a new contraceptive method?
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J
Acta Eur Fertil; 1981 Sep; 12(3):275-6. PubMed ID: 6803498
[TBL] [Abstract][Full Text] [Related]
71. Administration of luteinizing hormone-releasing hormone analogs delays ovulation without affecting the luteal function in rhesus monkeys.
Borghi MR; Niesvisky R; Balmaceda JP; Coy DH; Schally AV; Asch RH
Fertil Steril; 1983 Nov; 40(5):678-82. PubMed ID: 6414849
[TBL] [Abstract][Full Text] [Related]
72. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
Yen SS
Fertil Steril; 1983 Mar; 39(3):257-66. PubMed ID: 6130985
[TBL] [Abstract][Full Text] [Related]
73. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
Lemay A; Quesnel G
Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
[TBL] [Abstract][Full Text] [Related]
74. A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.
Goldman JA; Dicker D; Feldberg D; Ashkenazi J; Voliowich I
Hum Reprod; 1994 Feb; 9(2):226-8. PubMed ID: 8027276
[TBL] [Abstract][Full Text] [Related]
75. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue - a new approach to birth control?
Nillius SJ; Bergquist C; Wide L
Contraception; 1978 Jun; 17(6):537-44. PubMed ID: 363344
[TBL] [Abstract][Full Text] [Related]
76. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging.
Andreyko JL; Blumenfeld Z; Marshall LA; Monroe SE; Hricak H; Jaffe RB
Am J Obstet Gynecol; 1988 Apr; 158(4):903-10. PubMed ID: 2966587
[TBL] [Abstract][Full Text] [Related]
77. [The use of peptides for contraception].
Korkhov VV
Akush Ginekol (Mosk); 1987 Sep; (9):9-10. PubMed ID: 3322081
[TBL] [Abstract][Full Text] [Related]
78. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol.
Franssen AM; van der Heijden PF; Thomas CM; Doesburg WH; Willemsen WN; Rolland R
Fertil Steril; 1992 May; 57(5):974-9. PubMed ID: 1533376
[TBL] [Abstract][Full Text] [Related]
79. Vaginal progesterone for contraception.
Victor A; Jackanicz TM; Johansson ED
Fertil Steril; 1978 Dec; 30(6):631-5. PubMed ID: 729823
[TBL] [Abstract][Full Text] [Related]
80. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
